327 related articles for article (PubMed ID: 23041722)
1. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
2. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
[TBL] [Abstract][Full Text] [Related]
3. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
[TBL] [Abstract][Full Text] [Related]
4. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Durrieu F; Geneviève F; Arnoulet C; Brumpt C; Capiod JC; Degenne M; Feuillard J; Garand R; Kara-Terki A; Kulhein E; Maynadié M; Ochoa-Noguera ME; Plesa A; Roussel M; Eghbali H; Truchan-Graczyk M; de Carvalho Bittencourt M; Feugier P; Béné MC
Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
[TBL] [Abstract][Full Text] [Related]
5. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
6. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
8. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
9. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
10. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
12. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
[TBL] [Abstract][Full Text] [Related]
13. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens.
Rawstron AC; de Tute R; Jack AS; Hillmen P
Leukemia; 2006 Dec; 20(12):2102-10. PubMed ID: 17051247
[TBL] [Abstract][Full Text] [Related]
15. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of immunophenotype characteristics in 109 cases of B lineage chronic B lymphoid leukemia].
Wang AQ; Geng MJ; Zhu MQ; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1374-7. PubMed ID: 22169286
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric analysis of CD5+ B cells: a frame of reference for minimal residual disease analysis in chronic lymphocytic leukemia.
Gupta R; Jain P; Deo SV; Sharma A
Am J Clin Pathol; 2004 Mar; 121(3):368-72. PubMed ID: 15023041
[TBL] [Abstract][Full Text] [Related]
18. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
19. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]